506 related articles for article (PubMed ID: 12072190)
1. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient.
Knutson KL; Disis ML
Hum Immunol; 2002 Jul; 63(7):547-57. PubMed ID: 12072190
[TBL] [Abstract][Full Text] [Related]
2. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
Knutson KL; Schiffman K; Cheever MA; Disis ML
Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
[TBL] [Abstract][Full Text] [Related]
3. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
4. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.
Knutson KL; Schiffman K; Disis ML
J Clin Invest; 2001 Feb; 107(4):477-84. PubMed ID: 11181647
[TBL] [Abstract][Full Text] [Related]
5. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
Zaks TZ; Rosenberg SA
Cancer Res; 1998 Nov; 58(21):4902-8. PubMed ID: 9809997
[TBL] [Abstract][Full Text] [Related]
6. Human leucocyte antigen-A2 restricted and Mycobacterium tuberculosis 19-kDa antigen-specific CD8+ T-cell responses are oligoclonal and exhibit a T-cell cytotoxic type 2 response cytokine-secretion pattern.
Höhn H; Kortsik C; Nilges K; Necker A; Freitag K; Tully G; Neukirch C; Maeurer MJ
Immunology; 2001 Nov; 104(3):278-88. PubMed ID: 11722642
[TBL] [Abstract][Full Text] [Related]
7. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.
Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic activity and lymphokine production of T cell receptor (TCR)-alpha beta+ and TCR-gamma delta+ cytotoxic T lymphocyte (CTL) clones recognizing HLA-A2 and HLA-A2 mutants. Recognition of TCR-gamma delta+ CTL clones is affected by mutations at positions 152 and 156.
Spits H; Paliard X; Engelhard VH; de Vries JE
J Immunol; 1990 Jun; 144(11):4156-62. PubMed ID: 2111341
[TBL] [Abstract][Full Text] [Related]
9. CDR3α drives selection of the immunodominant Epstein Barr virus (EBV) BRLF1-specific CD8 T cell receptor repertoire in primary infection.
Kamga L; Gil A; Song I; Brody R; Ghersi D; Aslan N; Stern LJ; Selin LK; Luzuriaga K
PLoS Pathog; 2019 Nov; 15(11):e1008122. PubMed ID: 31765434
[TBL] [Abstract][Full Text] [Related]
10. Human CD8+ T cells from TB pleurisy respond to four immunodominant epitopes in Mtb CFP10 restricted by HLA-B alleles.
Li L; Yang B; Yu S; Zhang X; Lao S; Wu C
PLoS One; 2013; 8(12):e82196. PubMed ID: 24349220
[TBL] [Abstract][Full Text] [Related]
11. Human TCR-gamma/delta alloreactive response to HLA-DR molecules. Comparison with response of TCR-alpha/beta.
Flament C; Benmerah A; Bonneville M; Triebel F; Mami-Chouaib F
J Immunol; 1994 Oct; 153(7):2890-904. PubMed ID: 8089476
[TBL] [Abstract][Full Text] [Related]
12. A single TCR alpha-chain with dominant peptide recognition in the allorestricted HER2/neu-specific T cell repertoire.
Liang X; Weigand LU; Schuster IG; Eppinger E; van der Griendt JC; Schub A; Leisegang M; Sommermeyer D; Anderl F; Han Y; Ellwart J; Moosmann A; Busch DH; Uckert W; Peschel C; Krackhardt AM
J Immunol; 2010 Feb; 184(3):1617-29. PubMed ID: 20042572
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of escape from CD8+ T-cell clones specific for the HER-2/neu proto-oncogene expressed in ovarian carcinomas: related and unrelated to decreased MHC class 1 expression.
Kono K; Halapi E; Hising C; Petersson M; Gerdin E; Vanky F; Kiessling R
Int J Cancer; 1997 Jan; 70(1):112-9. PubMed ID: 8985099
[TBL] [Abstract][Full Text] [Related]
14. Frequent contribution of T cell clonotypes with public TCR features to the chronic response against a dominant EBV-derived epitope: application to direct detection of their molecular imprint on the human peripheral T cell repertoire.
Lim A; Trautmann L; Peyrat MA; Couedel C; Davodeau F; Romagné F; Kourilsky P; Bonneville M
J Immunol; 2000 Aug; 165(4):2001-11. PubMed ID: 10925283
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer.
Kono K; Takahashi A; Sugai H; Fujii H; Choudhury AR; Kiessling R; Matsumoto Y
Clin Cancer Res; 2002 Nov; 8(11):3394-400. PubMed ID: 12429626
[TBL] [Abstract][Full Text] [Related]
16. CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers.
Datta J; Xu S; Rosemblit C; Smith JB; Cintolo JA; Powell DJ; Czerniecki BJ
Cancer Immunol Res; 2015 May; 3(5):455-63. PubMed ID: 25791067
[TBL] [Abstract][Full Text] [Related]
17. Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells.
Henle AM; Erskine CL; Benson LM; Clynes R; Knutson KL
J Immunol; 2013 Jan; 190(1):479-88. PubMed ID: 23180824
[TBL] [Abstract][Full Text] [Related]
18. A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102.
Karyampudi L; Formicola C; Erskine CL; Maurer MJ; Ingle JN; Krco CJ; Wettstein PJ; Kalli KR; Fikes JD; Beebe M; Hartmann LC; Disis ML; Ferrone S; Ishioka G; Knutson KL
Clin Cancer Res; 2010 Feb; 16(3):825-34. PubMed ID: 20103660
[TBL] [Abstract][Full Text] [Related]
19. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
[TBL] [Abstract][Full Text] [Related]
20. Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.
Voss RH; Kuball J; Engel R; Guillaume P; Romero P; Huber C; Theobald M
Immunol Res; 2006; 34(1):67-87. PubMed ID: 16720899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
